trending Market Intelligence /marketintelligence/en/news-insights/trending/653ilzCWqtt09wovovX6hw2 content esgSubNav
In This List

Medivir completes sale of pharma unit to Karo Pharma

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Medivir completes sale of pharma unit to Karo Pharma

Medivir AB completed the divestment of its unit BioPhausia AB to Stockholm-based Karo Pharma AB.

The Medivir board will propose that net proceeds from the sale, about 870 million Swedish kronor, or 32 kronor per share, be transferred to Medivir shareholders through a voluntary share redemption offer. The board will convene a general meeting by early January 2017.

Stockholm-based Medivir is a molecular diagnostics company that develops epigenetic tests for cancer assessment.

As of Dec. 15, US$1 was equivalent to 9.38 Swedish kronor.